Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes
Authors' conclusion
Liraglutide reduces plasma levels of numerous DhCer and Cer species in T2D patients, which may contribute to the cardiovascular benefit observed in the LEADER trial. The independent association between the decrease in plasma DhCer level with the reduction in LFC and TyG index adds new insights regarding the relationship between DhCer, liver steatosis and insulin resistance.
Study context
- Population
- Patients with T2D treated with liraglutide 1.2 mg/day for 6 months, and controlsLiver fat content (LFC) assessed in 53
- Participants
- 35 vs 86
- Exposure
- T2D patients before vs after 6 months of liraglutide (1.2 mg/day); T2D patients vs controls at baseline
- Controlsn = 35reference
- T2Dn = 86
- Outcome
- Change in circulating levels of DhCer and Cer with liraglutide
- Follow-up
- 6 months
Methodological detailssingle-group liraglutide treatment, healthy controls for baseline comparison
- Single-group liraglutide treatment
- Healthy controls for baseline comparison
Main finding
As reported in the abstract
- Total dihydroceramides (DhCer) decreased after liraglutide
- 15.1% (p = 0.005)
- Total plasma ceramides (Cer) did not significantly change
- p = 0.18
Observational data: associations, not effects.
Further findings
Baseline DhCer and Cer, T2D vs controls
- Plasma total DhCer, 7 DhCer and 7 Cer species increased in T2D vs controls
Reduction in DhCer vs reduction in LFC and triglyceride-glucose (TyG) index · 6 months
- DhCer reduction independently associated with LFC reduction
- P = 0.0005
- DhCer reduction independently associated with TyG index reduction
- P = 0.05
- Multivariate analysis
Original publication
Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes. Cardiovasc Diabetol. Published 4 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →